Heart Transplantation: A Thirty-Year Perspective

Miniati, Douglas N.; Robbins, Robert C.

doi:10.1146/annurev.med.53.082901.104050

Cited by 81 publications

(47 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our own experience, establishment and coherent use of specifically liberalized acceptance criteria for marginal donors (Table 2) have been safe and successful for several years and are generally confirmed by others [158]. The strict use of the so-called 'Papworth protocol' of marginal donor management [125], together with comprehensive monitoring of the donor, has been shown to have the potential to increase substantially the numbers of donor hearts without adverse effects on the recipient [160].…”

Section: Resultsmentioning

confidence: 57%

Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience

Wittwer

Wahlers

2007

Transplant International

102

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 57%

Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience

Wittwer

Wahlers

2007

Transplant International

102

View full text Add to dashboard Cite

“…The majority of these patients at the end stage of disease will die while waiting for a heart transplant, presently the last treatment option, which, unfortunately, is very limited because donor organs are in short supply. 9 Restoration of cardiac function may be achieved by replacing diseased myocardium with a functional cardiac tissue, and therefore cardiac tissue engineering might offer a novel therapeutic modality to patients with malfunctioning myocardium. Additional work remains to demonstrate further if the engineered cardiac tissue can provide a therapeutic benefit for cardiovascular diseases.…”

Section: Clinical Perspective P 2237mentioning

confidence: 99%

Creation of Engineered Cardiac Tissue In Vitro From Mouse Embryonic Stem Cells

et al. 2006

View full text Add to dashboard Cite

Background-Embryonic stem (ES) cells can terminally differentiate into all types of somatic cells and are considered a promising source of seed cells for tissue engineering. However, despite recent progress in in vitro differentiation and in vivo transplantation methodologies of ES cells, to date, no one has succeeded in using ES cells in tissue engineering for generation of somatic tissues in vitro for potential transplantation therapy. Methods and Results-ES-D3 cells were cultured in a slow-turning lateral vessel for mass production of embryoid bodies.The embryoid bodies were then induced to differentiate into cardiomyocytes in a medium supplemented with 1% ascorbic acid. The ES cell-derived cardiomyocytes were then enriched by Percoll gradient centrifugation.

show abstract

“…Serial endomyocardial biopsies are the current clinical standard for graft monitoring; a patient initially undergoes 3-4 individual biopsies every second week after transplantation (1). The invasive procedure is deemed necessary because of the high rates of graft rejection (20% in the first year) (2), but it can give rise to bleeding, infection, arrhythmia, pneumothorax, carotid puncture, ventricular perforation, and tricuspid insufficiency (3,4).…”

Section: Introductionmentioning

confidence: 99%

Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice

Świrski¹,

Wildgruber²,

Ueno³

et al. 2010

J. Clin. Invest.

View full text Add to dashboard Cite

Rates of graft rejection are high among recipients of heart transplants. The onset and progression of clinically significant heart transplant rejection are currently monitored by serial biopsy, but this approach is highly invasive and lacks sensitivity. Here, we have developed what we believe to be a new technique to measure organ rejection noninvasively that involves the exploration of tissue-infiltrating leukocytes as biomarker sources for diagnostic imaging. Specifically, we profiled the myeloid response in a murine model of heart transplantation with the aim of defining and validating an imaging signature of graft rejection. Ly-6C hi monocytes, which promote inflammation, accumulated progressively in allografts but only transiently in isografts. Ly-6C lo monocytes, which help resolve inflammation, did not accumulate, although they composed the majority of the few remaining monocytes in isografts. The persistence of Ly-6C hi monocytes in allografts prompted us to screen for a Ly-6C hi monocyte-associated imaging marker. Low-density array data revealed that Ly-6C hi monocytes express 10-fold higher levels of myeloperoxidase (MPO) than Ly-6C lo monocytes. Noninvasive magnetic resonance imaging of MPO with an MPO-activatable Gd-chelate revealed a spatially defined T1-weighted signal in rejected allografts but not in isografts or MPO-deficient allograft recipients. Flow cytometry, enzymography, and histology validated the approach by mapping MPO activity to Ly-6C hi monocytes and neutrophils. Thus, MPO imaging represents a potential alternative to the current invasive clinical standard by which transplants are monitored.

show abstract

Heart Transplantation: A Thirty-Year Perspective

Cited by 81 publications

References 53 publications

Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience

Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience

Creation of Engineered Cardiac Tissue In Vitro From Mouse Embryonic Stem Cells

Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice

Contact Info

Product

Resources

About